Evidence map›Paper›PMID 41220922›Full record

ArticleCase reports in hematology2025

Heterogeneous Presentations of iMCD: A Single-Institution Case Series.

Jaspreet Kaur, Anthony Sisk, Jonathan E Zuckerman, Haifaa Abdulhaq

Abstract readCase Reports
In one paragraph

Article in Case reports in hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jaspreet KaurDivision of Hematology/Oncology, University of California San Francisco, Fresno 93701-2302, California, USA.ORCID https://orcid.org/0000-0002-4125-5355
Anthony SiskDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles 90095, California, USA.ORCID https://orcid.org/0000-0001-7262-3985
Jonathan E ZuckermanDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles 90095, California, USA.ORCID https://orcid.org/0000-0001-9758-2147
Haifaa AbdulhaqDivision of Hematology/Oncology, University of California San Francisco, Fresno 93701-2302, California, USA.ORCID https://orcid.org/0000-0002-3549-0981

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Idiopathic multicentric Castleman disease (iMCD) is a rare lymphadenopathic disorder characterized by hyperplasia of multiple lymph nodes and can be associated with a wide range of symptoms and presentations, from mild disease to life-threatening organ failure. Varied histopathological features and heterogeneous presentation of this rare entity can make the diagnosis quite challenging for both hematologists and other specialists who may encounter patients at various stages of disease progression. Method: We analyze five different clinical presentations at our institution to demonstrate challenging routes of diagnosis and treatment complexities of iMCD. We aim to raise awareness to the importance of early diagnosis and appropriate management of this rare condition. Results: All patients in this series presented with symptomatic lymphadenopathy. We highlight one rare instance of thrombocytopenia, anasarca/ascites, fever, reticulin fibrosis or renal dysfunction, and organomegaly (TAFRO) syndrome with elusive iMCD, which illustrates the challenges in the diagnosis of this rare condition and the importance of early recognition of its symptoms to avoid decompensation of patients. We also review established treatment guidelines and response criteria to siltuximab as outlined in the international consensus treatment guidelines. Conclusion: These cases highlight the heterogeneity and challenging diagnosis of this rare cytokine-driven hematological disorder and the role of siltuximab in the treatment of iMCD.

Indexed as

diagnosisidiopathic multicentric Castleman diseasesiltuximabTAFRO

Identifiers

PMID41220922
PMCPMC12602032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.